BCR and B-cell chronic lymphocytic leukemia: Preliminary data from a phase 1b trial in CLL and B-NHL have been reported.102 The drug was well tolerated and displayed the typical early effects of BCR inhibitors, including the initial rise in absolute lymphocyte counts and the simultaneous reduction in lymphadenopathy.